对放射性免疫治疗的分歧反应是由瘤微环境的内在特征来定义的
Jacob Gadwa1, Justin Yu2, Miles Piper3
1Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
Journal for immunotherapy of cancer
|January 8, 2025
概括
组合免疫疗法在临床前癌症模型中显示出差异性疗效. 调节性T细胞 (Tregs) 在胰腺癌中驱动抗性,但它们的枯竭恢复了治疗的有效性,突出了瘤微环境.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 临床前模型 临床前模型
背景情况:
- 免疫疗法的有效性在不同类型的癌症中存在显著差异.
- 响应与进展背后的机制尚不清楚.
- 有限的临床前模型准确地反映了不同癌症对治疗的反应.
研究的目的:
- 开发临床前模型,对组合免疫疗法产生对比的反应.
- 研究瘤微环境在免疫疗法耐药性中的作用.
- 确定克服免疫疗法耐药性的策略.
主要方法:
- 使用组合放射免疫疗法 (PD-1阻断,IL2Rβγ偏差信号传输,OX40激动).
- 产生的头部和部状细胞癌 (HNSCC) 和胰腺管腺癌 (PDAC) 模型.
- 研究了调控性T细胞 (Treg) 枯竭的影响.
- 进行了异型瘤植入研究.
主要成果:
- PDAC模型显示瘤进展,而HNSCC模型对治疗有反应.
- 调控性T细胞 (Tregs) 在PDAC瘤中扩大,抑制CD8T细胞活性.
- 降低Treg降低恢复了治疗效果,并消除了反应差异.
- 瘤部位影响了治疗反应,HNSCC瘤在胰腺中进展.
结论:
- 瘤微环境 (TME) 在免疫治疗反应中起着至关重要的作用.
- 免疫和非免疫的TME组件有助于免疫抑制.
- 组合免疫疗法需要仔细考虑TME以获得最佳疗效.
相关概念视频
Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Cytotoxic T Cells-mediated Immune Response
841
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
841
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


